Liu, Jing http://orcid.org/0000-0002-3113-4015
Tokheim, Collin
Lee, Jonathan D. http://orcid.org/0000-0002-1229-0098
Gan, Wenjian http://orcid.org/0000-0001-7599-5020
North, Brian J.
Liu, X. Shirley http://orcid.org/0000-0003-4736-7339
Pandolfi, Pier Paolo http://orcid.org/0000-0002-5352-5295
Wei, Wenyi http://orcid.org/0000-0003-0512-3811
Funding for this research was provided by:
Damon Runyon Cancer Research Foundation (DRQ-04-20)
Breast Cancer Research Foundation (BCRF-20-100)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA253027)
Article History
Received: 30 January 2021
Accepted: 27 October 2021
First Online: 18 November 2021
Competing interests
: W.W. and P.P.P. are co-founders and stockholders of the Rekindle Therapeutics. X.S.L. is a cofounder, board member, SAB member, and consultant of GV20 Oncotherapy and its subsidiaries; stockholder of BMY, TMO, WBA, ABT, ABBV, and JNJ; and received research funding from Takeda, Sanofi, and Novartis. The remaining authors declare no competing interests.